NCT01164696View on ClinicalTrials.gov

A Prospective Observational Study to Evaluate the Quality of Life and the Costs in a Real Life Setting in Patients Who Are Treated With 90Y-Zevalin

CompletedOBSERVATIONAL
Enrollment

30

Participants

Timeline

Start Date

August 31, 2007

Primary Completion Date

May 31, 2009

Study Completion Date

May 31, 2009

Conditions
Lymphoma, FollicularNon-Hodgkin Lymphoma
Interventions
DRUG

[90]Y-ibritumomab tiuxetan (Zevalin, BAY86-5128)

Zevalin was administered according to the directives in the approved package leaflet.

Trial Locations (1)

Unknown

Many Locations

Sponsors

Lead Sponsor

Bayer
All Listed Sponsors
lead

Bayer

INDUSTRY